Detalhe da pesquisa
1.
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.
Blood
; 142(23): 1960-1971, 2023 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37647654
2.
Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia.
Blood
; 139(8): 1135-1146, 2022 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34543383
3.
Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma.
Am J Hematol
; 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38700035
4.
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study.
Am J Hematol
; 98(3): 449-463, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36594167
5.
Chronic lymphocytic leukaemia Australasian consensus practice statement.
Intern Med J
; 53(9): 1678-1691, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37743239
6.
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
Br J Haematol
; 196(5): 1209-1218, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34915592
7.
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up.
Blood
; 136(18): 2027-2037, 2020 10 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-32698195
8.
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Blood
; 136(18): 2038-2050, 2020 10 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-32731259
9.
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
Blood
; 134(11): 851-859, 2019 09 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31340982
10.
Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma.
Intern Med J
; 49(9): 1070-1080, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30816618
11.
Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma.
Intern Med J
; 49(4): 422-433, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30230156
12.
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
Blood
; 127(2): 208-15, 2016 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-26486789
13.
Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate-/high-dose cytarabine.
Eur J Haematol
; 2018 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29719925
14.
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet Oncol
; 18(3): 297-311, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28139405
15.
Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia.
Br J Haematol
; 198(4): 790-793, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35702012
16.
Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.
Haematologica
; 102(4): 765-772, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28011903
17.
Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).
Eur J Haematol
; 98(2): 97-105, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27537786
18.
Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil.
Intern Med J
; 47 Suppl 4: 5-10, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28685928
19.
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.
Future Oncol
; 12(3): 293-302, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26785287
20.
Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.
Nephrol Dial Transplant
; 30(10): 1774-9, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26188340